Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis

Khalid Eljaaly, Samah Alshehri, Ahmed Aljabri, Ivo Abraham, Mayar Al Mohajer, Andre C Kalil, David E. Nix

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Both typical and atypical bacteria can cause community-acquired pneumonia (CAP); however, the need for empiric atypical coverage remains controversial. Our objective was to evaluate the impact of antibiotic regimens with atypical coverage (a fluoroquinolone or combination of a macrolide/doxycycline with a β-lactam) to a regimen without atypical antibiotic coverage (β-lactam monotherapy) on rates of clinical failure (primary endpoint), mortality, bacteriologic failure, and adverse events, (secondary endpoints). Methods: We searched the PubMed, EMBASE and Cochrane Library databases for relevant RCTs of hospitalized CAP adults. We estimated risk ratios (RRs) with 95% confidence intervals (CIs) using a fixed-effect model, but used a random-effects model if significant heterogeneity (I 2 ) was observed. Results: Five RCTs with a total of 2011 patients were retained. A statistically significant lower clinical failure rate was observed with empiric atypical coverage (RR, 0.851 [95% CI, 0.732-0.99; P = 0.037]; I 2 = 0%). The secondary outcomes did not differ between the two study groups: mortality (RR = 0.549 [95% CI, 0.259-1.165, P = 0.118], I 2 = 61.434%) bacteriologic failure (RR = 0.816 [95% CI, 0.523-1.272, P = 0.369], I 2 = 0%), diarrhea (RR = 0.746 [95% CI, 0.311-1.790, P = 0.512], I 2 = 65.048%), and adverse events requiring antibiotic discontinuation (RR = 0.83 [95% CI, 0.542-1.270, P = 0.39], I 2 = 0%). Conclusions: Empiric atypical coverage was associated with a significant reduction in clinical failure in hospitalized adults with CAP. Reduction in mortality, bacterial failure, diarrhea, and discontinuation due to adverse effects were not significantly different between groups, but all estimates favored atypical coverage. Our findings provide support for the current guidelines recommendations to include empiric atypical coverage.

Original languageEnglish (US)
Article number385
JournalBMC Infectious Diseases
Volume17
Issue number1
DOIs
StatePublished - Jun 2 2017

Fingerprint

Meta-Analysis
Pneumonia
Odds Ratio
Confidence Intervals
Bacteria
Lactams
Anti-Bacterial Agents
Mortality
Diarrhea
Doxycycline
Fluoroquinolones
Macrolides
PubMed
Libraries
Databases
Guidelines

Keywords

  • Antibiotics
  • Atypical
  • Community-acquired pneumonia
  • Fluoroquinolones
  • Macrolides

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia : A systematic review and meta-analysis. / Eljaaly, Khalid; Alshehri, Samah; Aljabri, Ahmed; Abraham, Ivo; Al Mohajer, Mayar; Kalil, Andre C; Nix, David E.

In: BMC Infectious Diseases, Vol. 17, No. 1, 385, 02.06.2017.

Research output: Contribution to journalArticle

@article{986d17687f9244dfba5ce0d2d80541ac,
title = "Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis",
abstract = "Background: Both typical and atypical bacteria can cause community-acquired pneumonia (CAP); however, the need for empiric atypical coverage remains controversial. Our objective was to evaluate the impact of antibiotic regimens with atypical coverage (a fluoroquinolone or combination of a macrolide/doxycycline with a β-lactam) to a regimen without atypical antibiotic coverage (β-lactam monotherapy) on rates of clinical failure (primary endpoint), mortality, bacteriologic failure, and adverse events, (secondary endpoints). Methods: We searched the PubMed, EMBASE and Cochrane Library databases for relevant RCTs of hospitalized CAP adults. We estimated risk ratios (RRs) with 95{\%} confidence intervals (CIs) using a fixed-effect model, but used a random-effects model if significant heterogeneity (I 2 ) was observed. Results: Five RCTs with a total of 2011 patients were retained. A statistically significant lower clinical failure rate was observed with empiric atypical coverage (RR, 0.851 [95{\%} CI, 0.732-0.99; P = 0.037]; I 2 = 0{\%}). The secondary outcomes did not differ between the two study groups: mortality (RR = 0.549 [95{\%} CI, 0.259-1.165, P = 0.118], I 2 = 61.434{\%}) bacteriologic failure (RR = 0.816 [95{\%} CI, 0.523-1.272, P = 0.369], I 2 = 0{\%}), diarrhea (RR = 0.746 [95{\%} CI, 0.311-1.790, P = 0.512], I 2 = 65.048{\%}), and adverse events requiring antibiotic discontinuation (RR = 0.83 [95{\%} CI, 0.542-1.270, P = 0.39], I 2 = 0{\%}). Conclusions: Empiric atypical coverage was associated with a significant reduction in clinical failure in hospitalized adults with CAP. Reduction in mortality, bacterial failure, diarrhea, and discontinuation due to adverse effects were not significantly different between groups, but all estimates favored atypical coverage. Our findings provide support for the current guidelines recommendations to include empiric atypical coverage.",
keywords = "Antibiotics, Atypical, Community-acquired pneumonia, Fluoroquinolones, Macrolides",
author = "Khalid Eljaaly and Samah Alshehri and Ahmed Aljabri and Ivo Abraham and {Al Mohajer}, Mayar and Kalil, {Andre C} and Nix, {David E.}",
year = "2017",
month = "6",
day = "2",
doi = "10.1186/s12879-017-2495-5",
language = "English (US)",
volume = "17",
journal = "BMC Infectious Diseases",
issn = "1471-2334",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia

T2 - A systematic review and meta-analysis

AU - Eljaaly, Khalid

AU - Alshehri, Samah

AU - Aljabri, Ahmed

AU - Abraham, Ivo

AU - Al Mohajer, Mayar

AU - Kalil, Andre C

AU - Nix, David E.

PY - 2017/6/2

Y1 - 2017/6/2

N2 - Background: Both typical and atypical bacteria can cause community-acquired pneumonia (CAP); however, the need for empiric atypical coverage remains controversial. Our objective was to evaluate the impact of antibiotic regimens with atypical coverage (a fluoroquinolone or combination of a macrolide/doxycycline with a β-lactam) to a regimen without atypical antibiotic coverage (β-lactam monotherapy) on rates of clinical failure (primary endpoint), mortality, bacteriologic failure, and adverse events, (secondary endpoints). Methods: We searched the PubMed, EMBASE and Cochrane Library databases for relevant RCTs of hospitalized CAP adults. We estimated risk ratios (RRs) with 95% confidence intervals (CIs) using a fixed-effect model, but used a random-effects model if significant heterogeneity (I 2 ) was observed. Results: Five RCTs with a total of 2011 patients were retained. A statistically significant lower clinical failure rate was observed with empiric atypical coverage (RR, 0.851 [95% CI, 0.732-0.99; P = 0.037]; I 2 = 0%). The secondary outcomes did not differ between the two study groups: mortality (RR = 0.549 [95% CI, 0.259-1.165, P = 0.118], I 2 = 61.434%) bacteriologic failure (RR = 0.816 [95% CI, 0.523-1.272, P = 0.369], I 2 = 0%), diarrhea (RR = 0.746 [95% CI, 0.311-1.790, P = 0.512], I 2 = 65.048%), and adverse events requiring antibiotic discontinuation (RR = 0.83 [95% CI, 0.542-1.270, P = 0.39], I 2 = 0%). Conclusions: Empiric atypical coverage was associated with a significant reduction in clinical failure in hospitalized adults with CAP. Reduction in mortality, bacterial failure, diarrhea, and discontinuation due to adverse effects were not significantly different between groups, but all estimates favored atypical coverage. Our findings provide support for the current guidelines recommendations to include empiric atypical coverage.

AB - Background: Both typical and atypical bacteria can cause community-acquired pneumonia (CAP); however, the need for empiric atypical coverage remains controversial. Our objective was to evaluate the impact of antibiotic regimens with atypical coverage (a fluoroquinolone or combination of a macrolide/doxycycline with a β-lactam) to a regimen without atypical antibiotic coverage (β-lactam monotherapy) on rates of clinical failure (primary endpoint), mortality, bacteriologic failure, and adverse events, (secondary endpoints). Methods: We searched the PubMed, EMBASE and Cochrane Library databases for relevant RCTs of hospitalized CAP adults. We estimated risk ratios (RRs) with 95% confidence intervals (CIs) using a fixed-effect model, but used a random-effects model if significant heterogeneity (I 2 ) was observed. Results: Five RCTs with a total of 2011 patients were retained. A statistically significant lower clinical failure rate was observed with empiric atypical coverage (RR, 0.851 [95% CI, 0.732-0.99; P = 0.037]; I 2 = 0%). The secondary outcomes did not differ between the two study groups: mortality (RR = 0.549 [95% CI, 0.259-1.165, P = 0.118], I 2 = 61.434%) bacteriologic failure (RR = 0.816 [95% CI, 0.523-1.272, P = 0.369], I 2 = 0%), diarrhea (RR = 0.746 [95% CI, 0.311-1.790, P = 0.512], I 2 = 65.048%), and adverse events requiring antibiotic discontinuation (RR = 0.83 [95% CI, 0.542-1.270, P = 0.39], I 2 = 0%). Conclusions: Empiric atypical coverage was associated with a significant reduction in clinical failure in hospitalized adults with CAP. Reduction in mortality, bacterial failure, diarrhea, and discontinuation due to adverse effects were not significantly different between groups, but all estimates favored atypical coverage. Our findings provide support for the current guidelines recommendations to include empiric atypical coverage.

KW - Antibiotics

KW - Atypical

KW - Community-acquired pneumonia

KW - Fluoroquinolones

KW - Macrolides

UR - http://www.scopus.com/inward/record.url?scp=85019972077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019972077&partnerID=8YFLogxK

U2 - 10.1186/s12879-017-2495-5

DO - 10.1186/s12879-017-2495-5

M3 - Article

C2 - 28576117

AN - SCOPUS:85019972077

VL - 17

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

SN - 1471-2334

IS - 1

M1 - 385

ER -